摘要
对50例维持性血透患者补充人类基因重组红细胞生成素(rHuEPO),观察其肾性贫血的纠正情况,结果体内促红细胞生成素(EPO)浓度由38.32±14.62mU/ml升到53.85±16.95mU/ml,略高于正常人群水平(48.00±17.70mU/ml),同时血红蛋白升至89±13g/L,红细胞压积28.6％±4.8％,贫血症状显著改善。并阐明EPO减少是血透患者肾性贫血的主要原因。此外,红细胞生长抑制因子、失血、缺铁性贫血、继发性甲状旁腺亢进、纤维性骨炎、铝中毒、红细胞寿命缩短也与血透患者贫血有关。认为用rHuEPO治疗能显著纠正肾性贫血,理想用药方法应选择皮下注射,治疗剂量应小剂量和个体化,保证治疗过程中有足够铁元素,并预防凝血、高血压等并发症的发生。
50 patients on chronic hemodialysis (HD) were selected in the study,male 30,female 20,age 40±10 years,weight 51±8 kg,hemoglobin (Hb) 53±60g/L,hematocrit (Hct)17. 6± 1. 5%. The erythropoietin (EPO) concentration of all the patients in vitro was low,383. 2±146. 2 mU/L. After supplying rHuEPO,the EPO concentration in vitro improved,about 53. 85±16. 95 mU/ml,higher than the lever of normal people (48. 00±17. 70mU/ml). At the same time.Hb enhanced to 89±13g/L,Hct 28. 6±4. 8% , the symptom and sign significantly improved. It was believed that reduction of EPO producing is the most important mechanism of renal failure anemia on
HD patients,erythropoietic inhibitors,blood loss,iron deficiency anemia,secondary hyperparathy-
roidism,hyperparathyroid bone disease,aluminum toxicity,reduced erythrocyte survial time are also
associated. rHuEPO therapy can correct the renal failure anemia with low dosage and individuation.
出处
《临床泌尿外科杂志》
北大核心
1995年第3期141-143,共3页
Journal of Clinical Urology
